Figure 3 | Scientific Reports

Figure 3

From: A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults

Figure 3

(a) Incidence of solicited systemic TRAEs by severity within 7 days after the first dose of the vaccine in the safety analysis set; (b) Incidence of solicited systemic TRAEs by severity within 7 days after the second dose of the vaccine in the safety analysis set; (c) Incidence of solicited local TRAEs by severity within 7 days after the first dose of the vaccine in the safety analysis set; (d) Incidence of solicited local TRAEs by severity within 7 days after the second dose of the vaccine in the safety analysis set. TRAE, treatment-related adverse event.

Back to article page